Emkay Global Financial Services Other Announcement

Merger & Restructuring

Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr

Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.

Value

₹30.00 Cr

Execution

Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals

Earnings Call

Emkay Global Financial Services Investor Presentation: Key Takeaways

Record Q2 FY27: consolidated revenue ₹1,567 Mn (+103% YoY) and PAT ₹310 Mn (+6,100% YoY). Wealth AUM ₹199,782 Mn (+9%); PMS+AIF AUM ₹25,624 Mn (+64%). Focus on distribution expansion and technology.

Financial ResultsAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Emkay Global Financial Services Q2 FY27 Results: Net Profit ₹31 Cr, Up 6100.0% YoY

Emkay Global Financial Services Ltd reported revenue from operations of ₹151.3 Cr (+109.8% YoY) and net profit of ₹31 Cr (+6100.0% YoY) for Q2 FY27.

Key figure

Net profit ₹31 Cr · +6100.0% YoY

Employee Stock Options

Emkay Global Financial Services Employee Stock Options

Emkay Global allotted 10,800 shares on ESOP exercises and granted 24,000 new stock options to employees. The options carry an exercise price of Rs 253.90 each.

Board Meeting Date

Emkay Global Financial Services Board Meeting Date

Emkay Global Financial Services has scheduled a board meeting for October 28, 2026, to consider its unaudited half-yearly financial results.

Convertible Warrants

Emkay Global Financial Services Convertible Warrants

Emkay Global received BSE listing approval for 1,00,000 shares converted from warrants to promoter Kacholia. Value: Rs. 2.40 Crore at Rs. 239.50 per share.

Value

₹2.40 Cr

Other AnnouncementAarti Pharmalabs Ltd AARTIPHARM

Aarti Pharmalabs Other Announcement

Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.

Other AnnouncementSagarsoft (India) Ltd SAGARSOFT

Sagarsoft (India) Other Announcement

Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.

Other AnnouncementSadhana Nitro Chem Ltd SADHNANIQ

Sadhana Nitro Chem Other Announcement

Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.

Other AnnouncementShriram Asset Management Company Ltd SRAMSET

Shriram Asset Management Company Other Announcement

Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.

Other AnnouncementJhandewalas Foods Ltd JHANDEWALAS

Jhandewalas Foods Other Announcement

Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.

Other AnnouncementAvience Biomedicals Ltd AVIENCE

Avience Biomedicals Other Announcement

Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.